Vorasidenib Maintenance for IDH Mutant Astrocytoma

NCT06809322 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

468

Enrollment

NETWORK

Sponsor class

Conditions

IDH-mutant Grade 2 or 3 Astrocytoma

Interventions

DRUG: Vorasidenib
DRUG: Vorasidenib Placebo

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]
[object Object]